Your cells run on ATP
During GLP-1associated weight loss, lean-mass changes are typically adaptive and preventable , not degenerative. GLP-1 Body Composition Changes: What Clinical Trials Show About Muscle Loss Clinical trials and body-composition sub-studies of semaglutide and tirzepatide consistently demonstrate: Fat mass accounts for most weight lost during treatment. Lean mass may decrease , particularly without resistance training or adequate protein intake. In many patients, the proportion of lean mass relative to total body weight is preserved or improved , because fat loss exceeds lean loss. Key clinical insight: GLP-1/GIP therapies improve overall body composition by preferentially reducing fat massnot by causing muscle breakdown. Lean mass refers to all the non-fat tissues in the bodyprimarily skeletal muscle , but also organs, bones, connective tissue, and body waterthat support metabolism, movement, and overall physical function

GLP-1 Receptor Biology The GLP-1 receptor (GLP-1R) is a class B GPCR (G-protein coupled receptor) expressed in pancreatic -cells, the hypothalamus, brainstem, heart, kidney, gastrointestinal tract, and lungs
Below is a summary (definitely not exhaustive) for the landscape of weight loss drugs in development (including company name and formulation, dosing and mechanism), showing my estimation of when these could launch and become available for patients
Evening injections shift those peaks to overnight, which some people prefer because they sleep through the worst of it
What makes TrimRx different from every other program on this list is the no-subscription model